Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Non-Small Cell Lung Cancer NSCLC
and you are
over 18
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This is a single-arm phase II clinical trial evaluating the safety and efficacy of the PD-L1 inhibitor durvalumab as first-line therapy in 50 patients with advanced NSCLC and ECOG Performance Status 2 (PS2).

Provided treatments

  • Drug: durvalumab
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02879617. The sponsor of the trial is Academic Thoracic Oncology Medical Investigators Consortium and it is looking for 50 volunteers for the current phase.
Official trial title:
A Phase II Clinical Trial Evaluating the Safety and Efficacy of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Patients With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2